Table 1

Completed and ongoing gene therapy clinical trials for nAMD

Trial registration numberExpressed geneVectorPhaseRoute of deliveryStatusSponsorLocationPatients (n)
NCT00109499PEDFAAV5IIntravitrealCompletedGenVecUSA28
NCT01494805sFLT01AAV2I/IISubretinalCompletedLions Eye Institute,
Adverum Biotechnologies
Australia40
NCT03748784AfliberceptAAV2IIntravitrealOngoingAdverum BiotechnologiesUSA30
NCT01024998sFLT01AAV2IIntravitrealCompletedSanofi GenzymeUSA19
NCT03066258Anti-VEGF FabAAV8I/IIaSubretinalOngoingRegenxbioUSA42
NCT01301443Endostatin and angiostatinEIAVISubretinalCompletedOxford BioMedicaUSA21
NCT03585556sCD59AAV2IIntravitrealOngoingHemera BiosciencesUSA25
  • AAV, adeno-associated viral vector; EIAV, equine infectious anaemia lentiviral vector; nAMD, neovascular age-related macular degeneration.